- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01831193
Effect of Oral Supplementation With Curcumin (Turmeric) in Patients With Proteinuric Chronic Kidney Disease
Study Overview
Detailed Description
Curcumin is a potent antioxidant found in extracts of the rhizome of the plant Curcuma longa L.
Different studies have demonstrated that curcumin has potent biological activity and therefore is an effective therapeutic agent for the treatment of various ailments.
This compound acts as a bifunctional antioxidant:
ه is capable of reacting directly with highly reactive oxygen species. ه acts indirectly by its ability to induce the expression of various cytoprotective proteins through Keap1/Nrf2/ARE pathway.
Although RAAS blockade is the cornerstone to prevent the progression of proteinuric nephropathy, a significant number of patients remained with proteinuria and progress to end-stage renal disease.
Due to the low cost and few side effects of curcumin, this could become an adjuvant treatment of proteinuric nephropathy purposes attenuate the progression of chronic kidney disease.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
DF
-
Mexico city, DF, Mexico, 14080
- Instituto Nacional de Cardiología Ignacio Chavez
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of proteinuric chronic kidney disease with 1g or more of proteins in a daily recollection.
- Individuals taking Angiotensin II Receptor Blocker or ACE inhibitors in monotherapy with maximum dose or in combination.
Exclusion Criteria:
- Hepatic damage.
- Malignancy.
- Pregnancy.
- Peritoneal or hemodialysis.
- Organ transplantation.
- Heart failure classification III or IV (New York Heart Association).
- History of chemotherapy within 2 years prior to screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Diabetic
|
Other Names:
|
Active Comparator: Non-diabetic
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in proteinuria
Time Frame: 8 weeks
|
8 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urologic Diseases
- Urological Manifestations
- Renal Insufficiency
- Urination Disorders
- Kidney Diseases
- Renal Insufficiency, Chronic
- Proteinuria
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Curcumin
Other Study ID Numbers
- 12-793
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Proteinuria
-
Universiteit AntwerpenCompleted
-
University of Sao PauloCompleted
-
Nantes University HospitalTerminated
-
Marshall UniversityUniversity at BuffaloRecruiting
-
Greater Boston Medical AssociatesMassachusetts General HospitalUnknownDecrease of Proteinuria With H.P. Acthar Gel and Its Effects on Clinical and Podocyte FunctionUnited States
-
Gulhane School of MedicineCompletedWe Searched for the Effects of Calcium Channel Blocker Amlodipine on the Clinical and Laboratory Parameters of Diabetic Patients With Proteinuria.Turkey
-
University of Mississippi Medical CenterCompletedPregnancy; Proteinuria, With Hypertension (Severe Pre-eclampsia) | Delivery; Proteinuria, With Gestational Hypertension (Pre-eclampsia, Severe) | Pregnancy; Hypertension, Gestational Hypertension, With Albuminuria (Severe Pre-eclampsia)United States
-
Zekai Tahir Burak Women's Health Research and Education...UnknownBasal Proteinuria in PregnancyTurkey
-
Brigham and Women's HospitalBristol-Myers SquibbCompleted
-
Xinhua Hospital, Shanghai Jiao Tong University...Unknown
Clinical Trials on Curcumin
-
H.K.E.S's S.Nijalingappa Institute of Dental Science...Unknown
-
Université de SherbrookeUnknown
-
Daniel DobererCompleted
-
Federico II UniversityCompleted
-
Kaiser PermanenteCompletedIrritable Bowel SyndromeUnited States
-
Woodbury, Michel, M.D.Lawson Health Research InstituteCompletedDepression | Schizophrenia | Schizoaffective DisorderPuerto Rico
-
Gary MorrowNational Cancer Institute (NCI)CompletedPain | Breast Carcinoma | Stage 0 Breast Cancer | Radiation-Induced DermatitisUnited States
-
Emory UniversityCompletedUterine Cervical DysplasiaUnited States
-
Louisiana State University Health Sciences Center...TerminatedMild Cognitive ImpairmentUnited States
-
University of North Carolina, Chapel HillColgate PalmoliveCompletedHalitosisUnited States